TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females greater than or equal to 50 years of age.~2. Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal to 4.~3. Brain imaging such as MRI and/or CT within one year of enrollment.~4. Subjects must have a guardian or caregiver who assists the subject at least 5 days per week (at least 3 hours/day).~5. Subjects must be able to cooperate with drug administration (including the ability to ingest oral medications) and study procedures and abide by study restrictions.~6. Subjects must have at least 6 years of prior education and should have previously (in pre-Alzheimer's condition) been capable of reading, writing and communicating effectively with others.~7. Subjects must be willing and able to give informed consent or have a mentally competent legal representative authorized to provide informed consent on their behalf.~8. Residence in an assisted care facility is allowed if subject is living independently.~Exclusion Criteria:~1. Major structural brain disease~2. Major medical illness or unstable medical condition within 6 months of screening that may interfere with the subject's ability to comply with study procedures and abide by study restrictions.~3. Residence in a nursing home or assisted care facility that provides the subject with 24-hour care and supervision.~4. Women who are pregnant, nursing, or if of child-bearing potential not using a medically accepted, highly effective method of birth control.~5. Active alcohol dependence or drug abuse.~6. Use of the following medications within 60 days prior to enrollment:cognition enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian medications, medications with central anticholinergic activity, medications for epilepsy, lithium.~7. Participation in an investigational drug or device study within 30 days prior to study entry, or 60 days prior to study entry if the investigational drug study involved therapy for Alzheimer's Disease.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dimebon (Type: EXPERIMENTAL): Dimebon 20 mg three times a day x 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 20 mg three times a day x 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Postherpetic Neuralgia in Herpes Zoster

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients of 50 years of age and older.~* Patients with a clinical diagnosis of uncomplicated herpes zoster presenting within the first 72 hours of vesicles.~* Patients who are willing and able to comply with the requirements of the study.~* Patients who are willing and able to give written informed consent.~* Average pain score pre-therapy greater or equal than 4 on 10-point Likert scale.~Exclusion Criteria:~* Sexually-active women of childbearing potential, including postmenopausal women less than 1 year since last menses, not employing adequate contraception (approved oral contraceptive, intrauterine device, barrier methods or total abstinence).~* Pregnant females and nursing mothers.~* Patients with immune dysfunction including congenital immune deficiency, active malignancy of any type, collagen vascular diseases, organ or bone marrow transplantations, known infection with HIV or severe atopic dermatitis.~* Patients who have received cytotoxic drugs or immunosuppressive therapy (e.g., chronic systemic corticosteroids) within the previous 3 months.~* Patients with evidence of cutaneous or visceral dissemination of herpes zoster infection (cutaneous dissemination is defined as \> 20 discrete lesions outside adjacent dermatomes).~* Patients who have received systemic anti-VZV medications or immunomodulatory medications (including interferon) within the previous 4 weeks.~* Patients currently receiving probenecid.~* Patients with impaired renal function: calculated creatinine clearance of \<30 mL/min using Cockcroft and Gault formula.~* Patients with abnormal liver function (alanine transaminase (ALT) or aspartate;transaminase (AST) levels greater than five times the upper limit of the normal range).~* Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir, famciclovir or gabapentin.~* Patients currently receiving therapy with gabapentin or tricyclic antidepressants.~* Patients with clinical evidence of ocular involvement of herpes zoster. Patients with herpes zoster of the ophthalmic branch of the trigeminal nerve without evidence of ocular involvement will be included.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HbA1c: 7.5-11.0%~* BMI: 25-40 kg/m2~Exclusion Criteria:~* Treatment with any OAD (Oral Antidiabetic Drugs) except metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Completed the SH-NEN-0003 study with relief of upper GI symptom. Relief is defined as last 7 days with a diary assessment of None or Minimal, but allowing up to 2 days to be rated as Mild during the 7-day period.~* A clinical diagnosis of a chronic condition (e.g., osteoarthritis or rheumatoid arthritis) that requires continuous daily NSAID treatment for at least 6 months. Daily NSAID treatment is defined as taking the prescribed dose for at least 5 of 7 days in any given week and can include COX-2 selective NSAIDs, multiple NSAIDs, and high-dose NSAIDs.~* Daily NSAID treatment dose and type:~* Must have been stable for at least 9 weeks prior to inclusion~* Are expected to remain stable for the duration of the study.~* Must be administered orally. If more than one type of NSAID treatment is used, at least one type must be administered orally.~* Hp negative on Histology performed at baseline endoscopy in the study SHNEN-0003.~Exclusion Criteria:~* Discontinuation from study SH-NEN-0003~* Pain, discomfort or burning in the upper abdomen precipitated by exercise or relieved by defecation.~* Pain, discomfort or burning in the upper abdomen not associated with the use of NSAIDs, including COX-2 selective NSAIDs.~* Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period as judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patents with myocardial infarction who have symptom onset within 12h before randomization; ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ; Corrected TIMI frame counted (cTFC) measured from the final angiographic imaging after PCI exceeding 40 frames; Signed informed consent form prior to trial participation.~Exclusion Criteria:~Coronary artery bypass surgery (CABG) history; Failed in stents implanting; Severe heart failure; Cardiogenic shock.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alprostadil (Type: EXPERIMENTAL): alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
- nitroglycerin (Type: PLACEBO_COMPARATOR): nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Reinforcing Mechanisms of Smoking in Adult ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* An age of 18 to 45 years~* A history of ADHD~* Current diagnosis of ADHD according to clinical criteria~* Current treatment with stimulant medication~* Smoking of 10 cigarettes or more per day~Exclusion Criteria:~* Treatment for any major medical illness such as cancer, heart disease, diabetes, skin diseases, current major depressive episode, and schizophrenia even if currently controlled by medication~* Current pregnancy, as measured by a pregnancy test (Clear Blue Easy, Unipath, Bedford, UK), or planning to become pregnant within the next 6 months. These individuals will not be included because smoking may cause harm to the unborn fetus~* Nursing mothers~* Non-English speaking people, because the majority of measurements used in the study have not been validated in languages other than English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- ADHD medication versus placebo (Type: EXPERIMENTAL): For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The participants were patients who continued treatment with adalimumab until the end of the treatment period in the NCT00870467(M06-859) study and provided informed consent to participate in the present follow-up survey.~Exclusion Criteria:~* Participants who used biological agents other than adalimumab after the period of treatment in the NCT00870467(M06-859) study were excluded from the present follow-up study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
- Non-Adalimumab (Type: None): Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Enstilar® in Daily Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Psoriasis vulgaris~* Lesions on trunk and/or extremities of at least mild severity~* Treatment with Enstilar® planned~* Signed informed consent to participate~Exclusion Criteria:~* Enrolled in any interventional clinical trial~* Ongoing or recent treatment with any systemic psoriasis~* Ongoing or recent treatment with UV-therapy~* Ongoing or previous treatment with Enstilar®~* Psoriasis of scalp only~* Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis~* More than 30% of surface area affected by psoriasis~* Any contraindications or known allergies to Enstilar® or its ingredients~* Incapacitated patients under institutionalized care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enstilar® (Type: None): Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Inadequate response to Methotrexate~* Must have been taking Methotrexate for at least 3 months at a minimal weekly dose of at least 15 mg and stable dose for 4 weeks prior to randomization~* American College of Rheumatology (ACR) global function status class 1-3~* Minimum of 6 swollen and 6 tender joints with evidence of synovitis in at least 1 hand or wrist~* High sensitivity C-reactive protein (hsCRP) ≥ 0.8 mg/dL~Exclusion Criteria:~* Previously received or currently receiving concomitant biologic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: PLACEBO_COMPARATOR): BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
- Arm 2 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 3 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 4 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate + Adalimumab Placebo
- Arm 5 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
- Arm 6 (Type: EXPERIMENTAL): BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
- Arm 7 (Type: ACTIVE_COMPARATOR): Adalimumab + Methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has had symptoms of painful diabetic neuropathy for at least 6 months and has a diagnosis of diabetes mellitus (Type I or Type II).~Exclusion Criteria:~* Subject has previously participated in this trial or subject has previously been assigned to treatment in a trial of the drug under investigation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide Standard Titration (ST) (Type: EXPERIMENTAL): Subjects had their dose titrated from 100 mg/day to 400 mg/day at weekly intervals of 100 mg. Subjects in this treatment group reach their target dose of 400 mg/day 3 weeks after Visit 2. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
- Lacosamide Fast Titration (FT) (Type: EXPERIMENTAL): Subjects receive 200 mg/day LCM for the first 3 days, 300 mg/day for the next 4 days, and reach their target dose of 400 mg/day after 1 week. They undergo sham titration for the remaining 3 weeks of the Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects underwent sham titration for the entire Titration Phase. All subjects completing the Titration Phase enter a 12-week Maintenance Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed a current IRB/IEC-approved informed consent form~* Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria~* On a stable regimen of antiparkinson's medications , including any levodopa preparation administered not less than three times daily, and willing to continue the same doses and regimens during study participation~* Experiencing troublesome dyskinesia following levodopa dosing (peak dose dyskinesia)~* Able to understand and complete a standardized PD home diary, following training~Exclusion Criteria:~* History of neurosurgical intervention related to Parkinson's disease (e.g. deep brain stimulation)~* History of seizures or stroke/TIA within 2 years of screening~* History of cancer within 5 years of screening, except adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer~* Estimated GFR \< 50 mL/min/1.73m2~* Presence of cognitive impairment, as evidenced by a Mini-Mental Status Examination (MMSE) score of less than 24 during screening~* If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose~* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment~* Treatment with an investigational drug or device within 30 days prior to screening~* Treatment with an investigational biologic within 6 months prior to screening

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: ACTIVE_COMPARATOR): Low dose ADS-5102 (amantadine extended release)
- Treatment C (Type: ACTIVE_COMPARATOR): A mid-dose ADS-5102 (amantadine extended release)
- Treatment D (Type: ACTIVE_COMPARATOR): High dose ADS-5102 (amantadine extended release)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-of-few Study of Pain Perception

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants~Exclusion Criteria:~* Cannot tolerate heat pain applied to the forearm/leg, based on a calibration task at the beginning of the experiment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- N-of-few Study of Pain (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete